Legend Biotech reports Q3 2026 loss despite revenue beat and margin outlook raise
Legend Biotech announced Q3 2026 results showing GAAP earnings of a $0.13 loss per share, missing consensus estimates, while revenue reached $359.5 million, up 32% year‑over‑year. CARVYKTI net trade sales rose 36% to $710 million, though U.S. sales were flat and international sales jumped 86%. The company also named a new CEO, received FDA clearance for the IND of LB2501, and lifted its Q4 product gross‑margin outlook to the high‑50% range.
Why it matters
The earnings miss may keep short‑term pressure on the stock, as noted by the pre‑market 13.2% drop. However, the revenue beat, strong CARVYKTI growth and higher margin guidance could support longer‑term upside, according to H.C. Wainwright’s reiterated Buy rating and $65 price target.
Key facts
- 1GAAP EPS was a loss of $0.13 per share, missing estimates by $0.13. seekingalpha.com
- 2Revenue was $359.5 million, a 32% year‑over‑year increase. seekingalpha.com
- 3Cash and cash equivalents totaled $853 million as of September 30, 2026. seekingalpha.com
- 4CARVYKTI net trade sales increased approximately 36% year‑over‑year to $710 million. finance.yahoo.com
- 5U.S. CARVYKTI sales were flat year‑over‑year, while sales outside the U.S. grew 86%. finance.yahoo.com
- 6Legend appointed a new CEO and announced FDA clearance of the IND for LB2501. investing.com
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.